RU58841 is being mixed with Minoxidil solution, but concerns arise about water causing instability. Mixing with water may lead to hydrolysis, potentially reducing effectiveness.
A user improved their hair health by taking 50,000 IU of vitamin D3 weekly due to a deficiency. Others discussed the potential link between vitamin D and hair growth, with some sharing similar experiences and emphasizing the importance of monitoring vitamin D levels and consulting with doctors.
The user has been taking 1mg of finasteride every other day for two months, experiencing improved hair quality but disrupted sleep. They are seeking advice on whether the sleep issues will improve with continued use or if they should stop the medication.
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
The conversation discusses concerns about potential side effects, specifically gynecomastia, from taking 1mg of finasteride every other day for hair loss. Bloodwork results were shared, but more information was requested to provide advice.
The conversation discusses hair loss and the ineffectiveness of a treatment called pyrilutamide, with one user experiencing negative results and questioning the product's authenticity.
The conversation is about the effectiveness of finasteride, oral minoxidil, and RU58841 for hair loss treatment. Opinions vary on improvement after 7 months of treatment, and there are concerns about the safety of using non-approved chemicals like RU58841.
The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
An 18-year-old experiencing hair loss seeks a finasteride prescription but faces skepticism from doctors who only recommend vitamins. A suggestion is made to consult a dermatologist for a proper diagnosis and potential treatment with finasteride or minoxidil.
A user's experience with hair loss treatments, specifically finasteride/dutasteride, and the potential for nocebo effects to influence side-effects. They caution others against focusing too much on possible side-effects when using these drugs, as they are generally safe and effective.
Dutasteride capsules should not be bitten or opened due to their foul taste and potential caustic effects. Users shared experiences of accidentally biting capsules and the unpleasant taste, with some suggesting swallowing techniques to avoid this.
The conversation is about adding a low dose of pyrilutamide to a hair loss treatment regimen. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation is about sourcing raw minoxidil and finasteride powder to mix with RU58841 for hair loss treatment. It warns against using raw minoxidil due to safety concerns.
The conversation discusses using topical finasteride for hair loss, with concerns about its safety around family members, especially pregnant women and infants. One user plans to try topical finasteride due to side effects from the pill.
A user took 1.5 mg Finasteride and topical Minoxidil for 11 months, resulting in significant changes in blood values but no noticeable hair improvement. They experienced side effects like mood swings and increased visceral fat, leading them to stop Finasteride.
The user plans to start a 12-month finasteride treatment to combat aggressive hair loss, with regular monitoring of thyroid levels, testosterone, DHT, liver enzymes, PSA, and iron levels. They seek advice on additional monitoring and aim to balance results with minimal side effects.
Minoxidil is highly toxic to pets, particularly cats and dogs, and there is a call for proper labeling to warn pet owners. Despite some skepticism about the effectiveness of petitions, many agree that awareness and caution are necessary to prevent accidental poisoning.
The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.
The user is considering adding Alfatradiol or Pyralutamide to their current hair loss treatment of oral Dutasteride and Minoxidil. They are seeking advice on experiences and purchasing options for these products in the US.
The user is using finasteride, HGH, GHK-CU, BPC-157, KPV, biotin/collagen/keratin vitamins, ketoconazole shampoo, and low-dose naltrexone to address hair loss, avoiding minoxidil due to past shedding experiences. Adenosine is discussed as a potential alternative to minoxidil, though it is noted to be expensive and hard to find.
Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.
The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.
Quitting RU58841 after over two years reduced scalp itching and inflammation, despite concerns about losing hair gains. The user continues using finasteride and oral minoxidil.
The user started using topical Minoxidil and Procapil, then added oral Minoxidil and Finasteride, seeing some hair thickening but no improvement in the frontal hairline. They believe nutrition, sleep, and lifestyle impact hair health and are seeking ways to track hairline and medication use.
The conversation is about a person starting treatment with RU58841 for hair loss. They are asked to share progress pictures to show if the treatment is effective.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
Finasteride improved hair appearance over seven years with no major side effects. Users discussed finasteride, minoxidil, and supplements like beta carotene and astaxanthin for hair loss treatment.
The user is using a regimen of topical finasteride (.025% concentration), minoxidil, Nutrafol, and vitamin D to address hair loss. They experienced initial side effects but reported improvement over 11 weeks and are considering increasing the dosage.